| Overview |
| bs-12676R-Cy7 |
| PRAM1 Polyclonal Antibody, Cy7 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog, Cow, Sheep, Pig, Horse |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PRAM1 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cell membrane |
| PML RAR; PML RARA regulated adaptor molecule 1; PML RARA target gene encoding an Adaptor Molecule 1; PML-RARA-regulated adapter molecule 1; PRAM 1; PRAM; PRAM-1; PRAM_HUMAN; PRAM1. |
| Complete remission of acute promyelocytic leukemia can be achieved by treating patients with retinoic acid, and PML-RAR-a (promyelocytic leukemia-retinoic acid receptor alpha fusion protein) plays a major role in mediating retinoic acid effects in leukemia cells. The retinoic acid-induced gene, PRAM-1 (PML-RAR-a target gene encoding an adaptor molecule 1) encodes an adaptor protein which is expressed and modulated during normal human myelopoiesis. PRAM-1 expression is hindered by expression of PML-RAR-a. The 718 amino acid PRAM-1 protein contains eight N-terminal proline-rich repeats and several proline residues that are clustered as type I or type II SH3 recognition motifs. PRAM-1 demonstrates expression in hematopoietic tissues and lung. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz